利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

84 records (took 0.042 seconds)

    Peptide Sequences and Compositions
    6.
    发明申请
    Peptide Sequences and Compositions 有权
    肽序列和组合物

    公开(公告)号：US20150182618A1

    公开(公告)日：2015-07-02

    申请号：US14656690

    申请日：2015-03-12

    Applicant: PepTcell, Ltd.

    Inventor： Gregory Alan Stoloff ,  Wilson Romero Caparros-Wanderlay

    IPC: A61K39/21 ,  C12N7/00 ,  C07K14/005

    CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/55544 ,  C07K14/005 ,  C07K2319/01 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16322 ,  C12N2740/16334

    Abstract: Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-4 that has the same length as the epitope: SEQ ID 1 GDTWAGVEAIIRILQQLLFIHFRIGCQHSR SEQ ID 2 KVGSLQYLALTALITPKKIKPPLPSVKKLTEDRWNKPQKT SEQ ID 3 EPVPLQLPPLERLTLDCSEDCGTSGTQ SEQ ID 4 YKGALDLSHFLKEKGGLEGLIYSQKRQDILDLWVYHTQGYFPD wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete HIV virus protein.

    Abstract translation: 提供的多肽具有不超过100个氨基酸，该多肽包含与SEQ ID 1-4中任一个具有至少60％同源性的一个或多个序列，或包含两个或多个具有7个氨基酸或更多个的表位，每个表位具有 与具有与表位相同长度的任何SEQ ID 1-4的亚序列具有至少60％的同源性：SEQ ID NO：1。GDTWAGVEAIIRILQQLLFIHFRIGCQHSR SEQ ID 2 KVGSLQYLALTALITPKKIKPPLPSVKKLTEDRWNKPQKT SEQ ID 3 EPVPLQLPPLERLTLDCSEDCGTSGTQ SEQ ID 4 YKGALDLSHFLKEKGGLEGLIYSQKRQDILDLWVYHTQGYFPD其中，该多肽是免疫原性的 表达主要组织相容性复合体（MHC）等位基因的脊椎动物，并且其中所述多肽不是完整的HIV病毒蛋白。

    EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION
    7.
    发明申请
    EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION 有权
    通过可变的有效抗原表面浓度聚焦

    公开(公告)号：US20150110836A1

    公开(公告)日：2015-04-23

    申请号：US14398084

    申请日：2013-05-21

    Applicant: DISTRIBUTED BIO, INC.

    Inventor： Jacob E. Glanville

    IPC: C07K14/005 ,  C12N7/00 ,  G06F19/22 ,  G06F19/18 ,  C40B50/02 ,  A61K39/21 ,  A61K38/46

    CPC classification number: C07K14/005 ,  A61K38/46 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/515 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/70 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12Y306/05002 ,  C40B50/02 ,  G06F19/18 ,  G06F19/22

    Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

    Abstract translation: 本公开提供了通过可变有效抗原表面浓度的表位聚焦来产生抗体或免疫原性组合物如疫苗的组合物和方法。 通常，本公开的组合物和方法包括三个步骤：包含一个或多个计算机生物信息学步骤的“设计过程”，以选择和产生用于免疫原性组合物的潜在抗原文库; 包括使用各种生化测定法进行潜在抗原的体外测试，以及进一步组合两种或多种抗原以产生一种或多种免疫原性组合物的“制剂方法” 和“施用”步骤，由此将免疫原性组合物施用于宿主动物，免疫细胞，受试者或患者。 还可以包括进一步的步骤，例如由免疫原性组合物的宿主免疫应答产生的抗体的分离和产生。

    Neuron-specific retrograde transport vector
    8.
    发明授权
    Neuron-specific retrograde transport vector 有权
    神经元特异性逆行运输载体

    公开(公告)号：US09006411B2

    公开(公告)日：2015-04-14

    申请号：US13988973

    申请日：2011-11-25

    Applicant: Kazuto Kobayashi

    Inventor： Kazuto Kobayashi

    IPC: C07K14/005 ,  A01N63/00 ,  A01N65/00 ,  C12N15/86 ,  A61K48/00

    CPC classification number: C12N15/86 ,  A61K48/0058 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/03 ,  C12N2740/16045 ,  C12N2740/16071 ,  C12N2760/20122 ,  C12N2760/20222 ,  C12N2810/6081

    Abstract: The present invention provides a lentiviral vector system having a higher titer, while sustaining an excellent retrograde transport ability, particularly, in the brain.The present invention also provides a kit for preparing a retrograde transport viral vector comprising: (1) a packaging plasmid containing the gag gene and the pol gene of HIV-1; (2) a packaging plasmid containing an accessory gene of HIV-1; (3) a transfer plasmid containing an target gene (a transgene); and (4) an envelope plasmid containing, as an envelope gene, a gene encoding a fused polypeptide comprising a fused extracellular domain consisting of the N-terminal region of an extracellular domain of rabies virus glycoprotein (RV-G) and the C-terminal region of an extracellular domain of vesicular stomatitis virus glycoprotein (VSV-G), a transmembrane domain of RV-G or VSV-G, and an intracellular domain of VSV-G, and the like.

    Abstract translation: 本发明提供了具有较高滴度的慢病毒载体系统，同时维持优异的逆行转运能力，特别是在脑中。 本发明还提供了用于制备逆行转运病毒载体的试剂盒，其包含：（1）含有HIV-1的gag基因和pol基因的包装质粒; （2）含有HIV-1辅助基因的包装质粒; （3）含有靶基因（转基因）的转移质粒; （4）包含作为包膜基因的包含编码融合多肽的基因的包膜质粒，所述融合多肽包含由狂犬病病毒糖蛋白（RV-G）的细胞外结构域的N末端区域构成的融合细胞外结构域和C-末端 水泡性口炎病毒糖蛋白（VSV-G）的细胞外结构域，RV-G或VSV-G的跨膜结构域和VSV-G的细胞内结构域等。

    SYSTEMS, METHODS AND COMPOSITIONS FOR OPTICAL STIMULATION OF TARGET CELLS
    10.
    发明申请
    SYSTEMS, METHODS AND COMPOSITIONS FOR OPTICAL STIMULATION OF TARGET CELLS 有权
    用于目标细胞光刺激的系统，方法和组合物

    公开(公告)号：US20110301529A1

    公开(公告)日：2011-12-08

    申请号：US13208419

    申请日：2011-08-12

    Applicant: Feng Zhang ,  Karl Deisseroth ,  Viviana Gradinaru

    Inventor： Feng Zhang ,  Karl Deisseroth ,  Viviana Gradinaru

    IPC: A61M37/00 ,  C12N13/00

    CPC classification number: A61N5/062 ,  A01K67/0333 ,  A01K2217/052 ,  A01K2227/703 ,  A01K2267/0356 ,  A61K38/00 ,  A61K48/005 ,  A61K48/0058 ,  A61K48/0083 ,  A61N5/0613 ,  A61N5/0622 ,  C07K14/00 ,  C07K14/195 ,  C07K14/215 ,  C12N13/00 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/16643 ,  C12N2740/16043 ,  C12N2740/16071 ,  C12N2750/14143 ,  C12N2830/002

    Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated NpHR-based molecule comprising a nucleic acid sequence that codes for light-activated NpHR-based molecule and a promoter. Either a high expression of the molecule manifests a toxicity level that is less than about 75%, or the light-activated NpHR-based proteins are expressed using at least two NpHR-based molecular variants. Each of the variants characterized in being useful for expressing a light-activated NpHR-based molecule that responds to light by producing an inhibitory current to dissuade depolarization of the neuron. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion pumps or for controlling inhibitory currents in a cell (e.g., in in vivo and in vitro environments).

    Abstract translation: 使用光，例如体内或体外，使用各种方法和装置来实施靶细胞的刺激。 一个实例涉及用于递送光激活的基于NpHR的分子的载体，其包含编码基于光激活的基于NpHR的分子和启动子的核酸序列。 分子的高表达表现出小于约75％的毒性水平，或者使用至少两种基于NpHR的分子变体表达光激活的NpHR基蛋白。 每个变体的特征在于可用于表达基于光激活的基于NpHR的分子，其通过产生抑制电流来抑制神经元的去极化来响应光。 其他方面和实施方案涉及用于离子泵的物质和分子的组合物，或用于控制细胞中的抑制性电流（例如在体内和体外环境中）的系统，方法，试剂盒，组合物。

Patent Agency Ranking